Sichuan Huiyu Pharmaceutical Co Ltd Market Cap ($665.11 Million)
Market Cap & Net Worth: Sichuan Huiyu Pharmaceutical Co Ltd (688553)
Sichuan Huiyu Pharmaceutical Co Ltd market cap. Sichuan Huiyu Pharmaceutical Co Ltd (SHG:688553) has a market capitalization of $665.11 Million (CN¥4.55 Billion) as of November 6, 2026. Listed on the SHG stock exchange, this China-based company holds position #10524 globally and #2796 in its home market, demonstrating a 1.32% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Sichuan Huiyu Pharmaceutical Co Ltd's stock price CN¥10.73 by its total outstanding shares 423600000 (423.60 Million). Also see Sichuan Huiyu Pharmaceutical Co Ltd (688553) cash flow conversion for how efficiently the company converts equity into cash flow.
Sichuan Huiyu Pharmaceutical Co Ltd Market Cap History (2021–2026)
Sichuan Huiyu Pharmaceutical Co Ltd market cap history from 2021 to 2026. Data shows change from $2.00 Billion to $665.11 Million (-22.27% CAGR). Check 688553 live share price for real-time trading data and today's change.
Sichuan Huiyu Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Sichuan Huiyu Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Sichuan Huiyu Pharmaceutical Co Ltd net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.86x
Sichuan Huiyu Pharmaceutical Co Ltd's market cap is 0.86 times its annual revenue
Latest Price to Earnings (P/E) Ratio
2.90x
Sichuan Huiyu Pharmaceutical Co Ltd's market cap is 2.90 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $2.00 Billion | $1.82 Billion | $445.86 Million | 1.10x | 4.49x |
| 2022 | $937.40 Million | $1.49 Billion | $248.99 Million | 0.63x | 3.76x |
| 2023 | $922.79 Million | $927.08 Million | $139.79 Million | 1.00x | 6.60x |
| 2024 | $942.19 Million | $1.09 Billion | $325.39 Million | 0.86x | 2.90x |
Competitor Companies of 688553 by Market Capitalization
Companies near Sichuan Huiyu Pharmaceutical Co Ltd in the global market cap rankings as of November 6, 2026. Also see 688553 total assets for a full breakdown of the balance sheet.
Key companies related to Sichuan Huiyu Pharmaceutical Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #514 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #538 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #588 globally with a market cap of $45.79 Billion USD ( CN¥312.89 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #621 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #514 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #538 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $47.80 |
| #588 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.79 Billion | CN¥49.05 |
| #621 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.50 |
Market Capitalization of Sichuan Huiyu Pharmaceutical Co Ltd (2021–2026)
Market capitalization of Sichuan Huiyu Pharmaceutical Co Ltd from 2021 to today. Between 2021 and today, Sichuan Huiyu Pharmaceutical Co Ltd's market cap moved from $2.00 Billion to $ 665.11 Million, with a yearly change of -22.27%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥665.11 Million | -39.69% |
| 2025 | CN¥1.10 Billion | +17.04% |
| 2024 | CN¥942.19 Million | +2.10% |
| 2023 | CN¥922.79 Million | -1.56% |
| 2022 | CN¥937.40 Million | -53.22% |
| 2021 | CN¥2.00 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Sichuan Huiyu Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $665.11 Million USD |
| MoneyControl | $665.11 Million USD |
| MarketWatch | $665.11 Million USD |
| marketcap.company | $665.11 Million USD |
| Reuters | $665.11 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Sichuan Huiyu Pharmaceutical Co Ltd
Sichuan Huiyu Pharmaceutical Co., Ltd. research and develops, produces, and sells anti-tumor injection in China and internationally. The company offers injection drug products, such as pemetrexed disodium, methrotraxate, docetaxel, azacitidine, oxaliplatin, cyclophosphamide, irinotecan hydrochloride, paclitaxel, bendamustine hydrochloride, decitabine, palonosetron hydrochloride, plerixafor, levet… Read more